Novo Nordisk A/S (NYSE:NVO) Given Average Rating of “Hold” by Analysts

Novo Nordisk A/S (NYSE:NVO) has earned an average recommendation of “Hold” from the twenty-four ratings firms that are covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, nineteen have given a hold rating and four have issued a buy rating on the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $65.5625.

Several equities research analysts recently commented on the stock. CICC Research assumed coverage on shares of Novo Nordisk A/S in a report on Friday, January 9th. They issued an “outperform” rating and a $73.50 price target for the company. Zacks Research raised shares of Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 10th. Wolfe Research assumed coverage on shares of Novo Nordisk A/S in a report on Thursday, March 26th. They issued a “peer perform” rating for the company. Jefferies Financial Group raised shares of Novo Nordisk A/S from an “underperform” rating to a “hold” rating in a report on Thursday, February 12th. Finally, Sanford C. Bernstein assumed coverage on shares of Novo Nordisk A/S in a report on Wednesday, March 18th. They issued an “outperform” rating and a $175.00 price target for the company.

Trending Headlines about Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Launched higher‑dose Wegovy (Wegovy HD 7.2 mg) nationwide in the U.S.; company says this dose delivers the largest weight-loss effect in the Wegovy franchise and is now broadly available, which should support prescription growth and higher average revenue per patient. Novo Nordisk launches higher-dose Wegovy in U.S.
• Positive Sentiment: Oral Wegovy pill rollout is expanding the obesity market by bringing in new patients (not just converting injectables), which can enlarge total addressable market and diversify revenue streams versus injectable GLP‑1s. Media coverage highlights early strong demand. Wegovy pill launch draws new patients
• Positive Sentiment: Company reaffirmed shareholder-friendly capital allocation with an ongoing share repurchase programme (part of up to DKK 15 billion over 12 months), a tangible near-term support for EPS and buy-side demand. Share repurchase programme
• Positive Sentiment: CEO commentary that the weight‑loss drug boom has “barely begun” reinforces management’s view of sustained demand and long runway for GLP‑1/obesity products, supporting bullish revenue forecasts. CEO: weight-loss boom has barely begun
• Neutral Sentiment: Partnerships/market ripple effects: other companies (e.g., Hims & Hers) are positioning to capture demand created by Novo’s products, which can expand distribution channels but are indirect to Novo’s near-term earnings. Hims & Hers taps into weight loss market
• Negative Sentiment: Analyst skepticism and downgrades citing GLP‑1 pipeline risks and competitive pressures (oral entrants from rivals like Lilly) highlight longer‑term execution and R&D risk that could pressure multiple expansion. Downgrade: GLP‑1 pipeline risks

Novo Nordisk A/S Price Performance

NYSE:NVO opened at $36.91 on Friday. The company has a debt-to-equity ratio of 0.61, a current ratio of 0.80 and a quick ratio of 0.57. The firm has a market cap of $164.78 billion, a price-to-earnings ratio of 10.64, a price-to-earnings-growth ratio of 8.75 and a beta of 0.73. The company has a 50 day moving average price of $42.36 and a 200-day moving average price of $49.38. Novo Nordisk A/S has a 1-year low of $35.12 and a 1-year high of $81.44.

Novo Nordisk A/S (NYSE:NVO) last posted its earnings results on Tuesday, February 3rd. The company reported $1.01 earnings per share for the quarter, beating the consensus estimate of $0.90 by $0.11. The firm had revenue of $12.43 billion during the quarter, compared to analyst estimates of $11.97 billion. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. Equities research analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Announces Dividend

The business also recently declared a dividend, which will be paid on Wednesday, April 8th. Investors of record on Monday, March 30th will be issued a $1.2751 dividend. This represents a yield of 723.0%. The ex-dividend date of this dividend is Monday, March 30th. Novo Nordisk A/S’s payout ratio is presently 50.43%.

Institutional Investors Weigh In On Novo Nordisk A/S

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Martin Capital Partners LLC boosted its stake in Novo Nordisk A/S by 53.8% during the 3rd quarter. Martin Capital Partners LLC now owns 117,577 shares of the company’s stock worth $6,524,000 after purchasing an additional 41,129 shares during the last quarter. Smith Chas P & Associates PA Cpas boosted its position in shares of Novo Nordisk A/S by 105.3% during the 3rd quarter. Smith Chas P & Associates PA Cpas now owns 405,425 shares of the company’s stock valued at $22,497,000 after acquiring an additional 207,959 shares during the last quarter. Clifford Swan Investment Counsel LLC boosted its position in shares of Novo Nordisk A/S by 13.7% during the 3rd quarter. Clifford Swan Investment Counsel LLC now owns 311,168 shares of the company’s stock valued at $17,267,000 after acquiring an additional 37,453 shares during the last quarter. Markel Group Inc. boosted its position in shares of Novo Nordisk A/S by 4.9% during the 3rd quarter. Markel Group Inc. now owns 2,368,649 shares of the company’s stock valued at $131,436,000 after acquiring an additional 110,061 shares during the last quarter. Finally, Cantor Fitzgerald Investment Advisors L.P. acquired a new position in shares of Novo Nordisk A/S during the 3rd quarter valued at about $1,294,000. Hedge funds and other institutional investors own 11.54% of the company’s stock.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.